Cancer Drug Resistance

🌟The article provides evidences for combining a #glutaminase inhibitor (CB-839) with an #HDAC inhibitor (panobinostat) to combat multiple myeloma (#MM), including bortezomib-resistant disease. Multiple myeloma, #glutaminolysis, #GLS1, HDAC inhibitor 👀oaepublish.com/articles/cdr.2…

🙌This comprehensive review systematically dissects the mechanisms of resistance to three novel #drug classes that have transformed multiple #myeloma (#MM) treatment in recent years. #CAR-T cells, #SINE, #selinexor 👀oaepublish.com/articles/cdr.2…

🙌This article presents a multi-omics framework that redefines patient stratification in acute myeloid leukemia (#AML) and offers mechanism-driven combination strategies to tackle #Venetoclax resistance. 👀oaepublish.com/articles/cdr.2…

🙌The new publish provides a systematic synthesis of the evolving #immunotherapy landscape in malignant pleural mesothelioma (#MPM) in #Cancer #DrugResistance. ✍️Immunotherapy resistance and strategies in malignant pleural mesothelioma 👀oaepublish.com/articles/cdr.2…

🙌The Original Article introducing a novel strategy to tackle multidrug resistance (#MDR) in cancer using conjugated oligoelectrolytes in #Cancer #DrugResistance. 👀Read: oaepublish.com/articles/cdr.2…

🌟Deadline is approaching! Call for Papers for Our Special Issue! 🩺"Overcoming Drug Resistance in Solid Tumors: Nanotechnology, Precision Medicine, and Multimodal Therapies" by Prof. Bingya Liu and Dr. Xi Cheng from @sjtu1896. ➡️z.l6j.cn/kL7xbC Deadline: 31 March 2026

Still waiting months for publication? Meet ScieRxiv — OAE’s new preprint platform: ⚡ Go live in 24h 🌍 Free & open access 💡 Zero submission fees Your research deserves to be seen NOW. ➡️scierxiv.com 📩preprint@scierxiv.com #OpenScience #Preprint #ResearchImpact

🙌The review provides a timely and in-depth look at how non-coding RNAs, particularly #microRNAs (miRNAs) and circular RNAs (#circRNAs), are reshaping our understanding of breast cancer (#BC) biology and treatment. oaepublish.com/articles/cdr.2…

🙌This review explores how six key post-translational modifications (#PTMs) of #EGFR—collectively regulate its #signaling, stability, and trafficking. ✍️Title: From EGFR PTM network to #TKI resistance: spatial subtypes and targeting in lung cancer oaepublish.com/articles/cdr.2…

🙌This review provides an in-depth analysis of the current landscape of #TROP2-directed antibody-drug conjugates (#ADCs). 🌟ADC resistance, TROP2, #breast cancer, ovarian carcinoma 👀oaepublish.com/articles/cdr.2…

🙌The article offering the first in vivo evidence linking #intracellular nucleotide metabolism to primary chemoresistance in Acute Myeloid Leukemia (#AML). peripheral blood mononuclear cells, bone marrow mononuclear cells ✍️Read: oaepublish.com/articles/cdr.2…

🙌The Original Article reveals how extracellular vesicles (#EVs) from multidrug-resistant #NSCLC cells point to SRC #inhibitors as promising chemosensitizers. ✍️extracellular vesicles, SRC inhibitors, #chemotherapy 👀oaepublish.com/articles/cdr.2…

📢The review highlights the pivotal and complex roles of circular RNAs (#circRNAs)—stable, loop-shaped non-coding RNAs—in driving or countering therapy resistance in NPC, OSCC, and LSCC. 👀oaepublish.com/articles/cdr.2…

🔔Excited to share insights from a comprehensive review on the evolving landscape of #breast cancer therapy in Cancer DrugResistance! Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment oaepublish.com/articles/cdr.2…

🌟The review highlights a critical mechanism behind #multidrug #resistance (MDR) in cancer: the #intercellular transfer of resistance via extracellular vesicles (EVs). Intercellular transfer of multidrug resistance mediated by extracellular vesicles 👀oaepublish.com/articles/cdr.2…

📢The review explores how competing endogenous RNAs (#ceRNAs) drive #resistance to #chemotherapy, targeted therapy, and #immunotherapy. Title: Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy 👀oaepublish.com/articles/cdr.2…

📢The review highlights the emerging functions of small extracellular #vesicles (sEVs) in driving #metabolic reprogramming and therapy resistance across multiple cancer types. 👀oaepublish.com/articles/cdr.2…

🔔This review highlights the urgent need to move beyond a one-size-fits-all approach in #ovarian cancer #immunotherapy. Title: Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies 🔍oaepublish.com/articles/cdr.2…

👏A comprehensive review by Dr. Tang & Dr. Kang explores how the transcription factor #NFE2L2 (NRF2) drives resistance to #ferroptosis—an iron-dependent form of regulated cell death—in cancer cells. 👉NFE2L2 and ferroptosis resistance in cancer therapy oaepublish.com/articles/cdr.2…

👏New publish in #Cancer #DrugResistance! Title: Novel anti-tumor strategies: targeting the crosstalk between cancer stem cells and cancer-associated #fibroblasts to resist drug resistance 👀oaepublish.com/articles/cdr.2…